Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cellectis has reached a significant milestone under its collaboration agreement with French research-based pharmaceutical firm Servier, in the preclinical development of two next-generation product candidates in solid tumors.
Subscribe to our email newsletter
As part of its collaboration agreement with the French firm, Cellectis is eligible for an undisclosed payment.
Signed in February 2014, the collaboration is focused on research, development and potentially commercialization of five product candidates targeting leukemia and solid tumors.
Cellectis is the gene-editing company that employs proprietary technologies to develop CAR T-cell products in adoptive immunotherapy for cancer.
Servier Oncology Innovation Therapeutic Pole director Jean-Pierre Abastado said: "We believe that immunotherapy will dramatically change the management of metastatic cancers.
"Our goal at Servier is to make these new technologies available for the largest number of cancer patients."
Servier’s development is driven by the pursuit of innovation in the therapeutic areas of cardiovascular, metabolic, central nervous system, psychiatric, rheumatologic diseases, as well as cancer.